1Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau
2Department of Political Science, National ChengKung University, Tainan, Taiwan
Background: This article sets up the initial discussion of the evolution of biopharmaceutical innovation in China through the perspective of sectoral innovation system (SIS). Methods: Two data sources including archival documentary data and field interviews were used in this study. Archival documentary data was collected from China Food and Drug Administration (CFDA) and Chinese National Knowledge Infrastructure (CNKI). In addition, industrial practitioners and leading researchers in academia were interviewed. Results: Biopharmaceutical in China was established through international knowledge transfer. The firms played more active role in commercializing biopharmaceutical in China though universities and research institutes were starting to interact with local firms and make contribution to biopharmaceutical industrialization. The transition of the Chinese government’s policies continuously shapes the evolution of biopharmaceutical sector. Policies have been dramatic changes before and after 1980s to encourage developing biopharmaceutical as a competitive industry for China. Conclusion: A SIS for biopharmaceutical has been shaped in China. However, currently biopharmaceutical is still a small sector in China, and for the further growth of the industry more synthetic policies should be implemented. Not only the policy supports towards the research and innovation of biopharmaceuticals in the early stage of development should be attended, but also commercialization of biopharmaceutical products in the later stage of sales.
Laage-Hellman J, Rickne A, McKelvey M, eds. The Economic Dynamics of Modern Biotechnology. Cheltenham: Edward Elgar; 2004.
McKelvey M. Evolutionary Innovations: The Business of Biotechnology. Oxford: Oxford University Press; 1996.
Brink J, McKelvey M, Smith K. Conceptualizing and measuring modern biotechnology. In: Laage-Hellman J, Rickne A, McKelvey M, eds. The Economic Dynamics of Modern Biotechnology. Cheltenham: Edward Elgar; 2004.
Kaiser R, Prange H. The reconfiguration of national innovation systems—the example of German biotechnology. Research Policy. 2004;33:395-408. doi:10.1016/j.respol.2003.09.001
Senker J. An overview of biotechnology in Europe: firms, demand, government policy and research. In: Laage-Hellman J, Rickne A, McKelvey M, eds. The Economic Dynamics of Modern Biotechnology. Cheltenham: Edward Elgar; 2004.
Huang S. How can innovation create the future in a catching-up economy? Focusing on China’s pharmaceutical industry. Journal of Knowledge-based Innovation in China. 2012;4:118-131. doi:10.1108/17561411211235721
Wang YT, Wu WT, Wu WJ. An overview and features of development of Chinese biopharmaceutical enterprises (in Chinese). Pharm Biotechnol. 2010;17:1-14.
Liu X, White S. Comparing innovation systems: a framework and application to China's transitional context. Research Policy. 2001;30:1091-1114. doi:10.1016/S0048-7333(00)00132-3
DHTI. Annual Report on Bioindustry in China. Beijing: Chemical Industry Press; 2010.
Chinese Pharmaceutical Enterprises Association (CPIA). The Report of the Development of Pharmaceutical Industry in China. Beijing: CPIA; 2009.
Liu FZ, Li GL. Review and prospect of the Good Manufacture Practice in China (in Chinese). Chinese Pharmaceutical Affairs. 2009;23:286-289.
Hu XW, Ma QJ, Zhang SY. Biopharmaceuticals in China (in Chinese). Biotechnol J. 2006;1:1215-1224.
Chen Z, Wang H-G, Wen Z-J, Wang Y-H. Life sciences and biotechnology in China. Philosophical Transactions of the Royal Society B. 2007;362:947-957. doi:10.1098/rstb.2007.2025
Chen YT, Luo LJ, Zhang YG. Development trajectories in the biotechnology industry: China versus leading countries. China & World Economy. 2011;19:105-123. doi:10.1111/j.1749-124X.2011.01245.x
Han P. China’s growing biomedical industry. Biologicals 2009;37:169-172.doi: 10.1016/j.biologicals.2009.02.010
Cai Y. Biotech Pharma: leading firm of antibody producer in the world (in Chinese). China High-Tech Enterprises. 2010;4:62-63.
Huashen Pharma: self-innovation for built-to-last (in Chinese). Chinese Journal of Interventional Radiology. 2007;1:92-94.
Bao FF. Development of Biopharmaceutical in China: An Analysis Based on Sectoral System of Innovation [master’s thesis]. Macau: University of Macau; 2011.
Frew SE, Sammut SM, Shore AF, et al. Chinese health biotech and the billion-patient market. Nature Biotechnol. 2008;26:37-53. doi:10.1038/nbt0108-37
Rezaie R, McGahan AM, Frew SE, Daar AS, Singer PA. Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators. Health Res Policy Syst. 2012;10:18-31. Doi:10.1186/1478-4505-10-18
Xu XY, Yu XM. Reform and prospect of higher education model in China (in Chinese). Chinese University Teaching. 2008;1:24-26.
Chinese Pharmaceutical Enterprises Association (CPIA). Development Report of Chinese Pharmaceutical Industry (1949-2009). Beijing: Chemical Industry Press; 2009.
Zhou Y, Xu GN, Su J, Minshall T. Barriers to entrepreneurial growth: an empirical study on university spin-offs in China. Journal of Science and Technology Policy in China. 2011;2:277-294. Doi:10.1108/17585521111167289
Wang JH, Chen T-Y, Tsai C-J. In search of an innovative state: the development of the biopharmaceutical industry in Taiwan, South Korea and China. Dev Change. 2012;43:481-503. Doi:10.1111/j.1467-7660.2012.01769.x
Su Y, Zhang DL, Guan ZH, Liu XB, Ao Y. A brief survey of building biopharmaceutical industrial parks (in Chinese). China Biotechnol. 2011;31:109-112.
Zhang F. Building biotech in Shanghai: a perspective of regional innovation system. Eur Plan Stud. 2015;23(10):2062-2078. Doi:10.1080/09654313.2014.1001322
Shi Y, Hu H, Wang Y. Technology uncertainty and technology sourcing: case study of biopharmaceuticals in China. International Journal of Business Innovation and Research. 2014;8:566-580. Doi:10.1504/IJBIR.2014.064614
Conglé M. China's regional economic development from a national perspective: the case of the biopharmaceutical industry. In: Leifner I, Wei DY, eds. Innovation and Regional Development in China. Oxon: Routledge; 2014.
Kukk P, Moors EH, Hekkert MP. The complexities in system building strategies—The case of personalized cancer medicines in England. Technol Forecast Soc Change. 2015;98:47-59. Doi:10.1016/j.techfore.2015.05.019
Chakma J, Sammut SM, Agrawal A. Life sciences venture capital in emerging markets. Nature Biotechnol. 2013;31:195-201. Doi:10.1038/nbt.2529
Zhang MY, Lu JJ, Wang L, et al. Development of Monoclonal Antibodies in China: overview and Prospects. BioMed Research International. 2015;2015:168935.
Zhang F, Cooke P, Wu F. State-sponsored research and development: a case study of China's biotechnology. Reg Stud. 2011;45:575-595. Doi:10.1080/00343401003604663
Salter B. Biomedical innovation and the geopolitics of patenting: China and the struggle for future territory. East Asian Science Technology and Society. 2011;5:341-357. Doi:10.1215/18752160-1408227
Xia C, Gautam A. Biopharma CRO industry in China: landscape and opportunities. Drug Discov Today. 2015;20(7):794-798. doi:10.1016/j.drudis.2015.02.007
Shi YZ, Hu H, Wang C. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation. Global Health. 2014;10:1-6. doi:10.1186/s12992-014-0078-4